Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: An open-label trial

Journal of Clinical Pharmacology

Volumn 50, Issue 6, 2010, Pages 647-658

  Lu, Jun ^a   Poppitt, Sally D ^a,b   Othman, Asma A ^b   Sunderland, Tracey ^a   Ruggiero, Katya ^c   Willett, Michael S ^c   Diamond, Lisa E ^c   Garcia, Wilfredo D ^c   Roesch, Benno G ^c   Cooper, Garth J S ^a,b,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Advanced Biomedical Research   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetylation; Metabolism; Pharmacodynamics; Pharmacokinetics; Triethylenetetramine

Indexed keywords

4 AMINOBENZOIC ACID; CAPTOPRIL; CIMETIDINE; DIGOXIN; DILTIAZEM; EDETIC ACID; FUROSEMIDE; INSULIN; MAGNESIUM SALICYLATE; METFORMIN; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; N1 ACETYLTRIETHYLENETETRAMINE; N1,N10 DIACETYLTRIETHYLENETETRAMINE; PARACETAMOL; SALICYLIC ACID; SIMVASTATIN; SPERMIDINE; TRIENTINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; HEART FAILURE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHENOTYPE; UNSPECIFIED SIDE EFFECT;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CHELATING AGENTS; COPPER; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; TIME FACTORS; TRIETHYLENETETRAMINE;

EID: 77953743734     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009349379     Document Type: Article

References (41)

1. Gu K., Cowie CC, Harris MI Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998 ; 21: 1138-1145.
2. Struthers AD, Morris AD Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002 ; 359: 1430-1432.
3. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003 ; 108: 1655-1661. (Pubitemid 37187795)
4. Doughty RN, Wright SP, Pearl A., et al. Randomized, controlled trial of integrated heart failure management: the Auckland Heart Failure Management Study. Eur Heart J. 2002 ; 23: 139-146.
5. Stamler J., Vaccaro O., Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993 ; 16: 434-444.
6. Fonarow GC The management of the diabetic patient with prior cardiovascular events. Rev Cardiovasc Med. 2003 ; 4: S38 - S49.
7. Cooper GJ, Phillips AR, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes. 2004 ; 53: 2501-2508.
8. Cooper GJ, Young AA, Gamble GD, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia. 2009 ; 52: 715-722.
9. Walshe JM Treatment of Wilsonĝ€™s disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982 ; 1: 643-647.
10. Cooper GJ, Chan YK, Dissanayake AM, et al. Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes. 2005 ; 54: 1468-1476.
11. Gong D., Lu J., Chen X., et al. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats. Mol Pharmacol. 2006 ; 70: 2045-2051.
12. Gong D., Lu J., Chen X., et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia. 2008 ; 51: 1741-1751.
13. Leggio L., Addolorato G., Abenavoli L., Gasbarrini G. Wilsonĝ€™s disease: clinical, genetic and pharmacological findings. Int J Immunopathol Pharmacol. 2005 ; 18: 7-14.
14. Kodama H., Murata Y., Iitsuka T., Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci. 1997 ; 61: 899-907.
15. Miyazaki K., Kishino S., Kobayashi M., Arashima S., Matsumoto S., Arita T. Determination of triethylenetetramine in plasma of patients by high-performance liquid chromatography. Chem Pharm Bull. 1990 ; 38: 1035-1038.
16. Nakano Y., Nohta H., Yoshida H., et al. Liquid chromatographic determination of triethylenetetramine in human and rabbit sera based on intramolecular excimer-forming fluorescence derivatization. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 ; 774: 165-172.
17. Tanabe R. Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilsonĝ€™s disease. Hokkaido Igaku Zasshi. 1996 ; 71: 217-228.
18. Gibbs KR, Walshe JM The metabolism of trientine: animal studies. In: Scheinberg IH, Walshe JM, eds. Orphan Diseases and Orphan Drugs. Manchester, UK: Manchester University Press in Association with the Fulbright Commission ; 1986: 33-42.
19. Kodama H., Meguro Y., Tsunakawa A., Nakazato Y., Abe T., Murakita H. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilsonĝ€™s disease. Tohoku J Exp Med. 1993 ; 169: 59-66.
20. Kobayashi M., Sugawara M., Saitoh H., Iseki K., Miyazaki K. Intestinal absorption and urinary excretion of triethylenetetramine for Wilsonĝ€™s disease in rat. Yakugaku Zasshi. 1990 ; 110: 759-763.
21. Takeda S., Ono E., Matsuzaki Y., et al. Metabolic fate of triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250) 3. Bioavailability of TJA-250 in rats after single administration. Oyo Yakuri. 1995 ; 49: 179-186.
22. Takeda S., Ono E., Wakui Y., et al. Metabolic fate of triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250) 2. Metabolism study in rats using 14C-TJA-250. Oyo Yakuri. 1995 ; 49: 173-178.
23. Takeda S., Ono E., Wakui Y., et al. Metabolic fate of triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250) 1. Absorption, distribution and excretion in rats after single administration of 14C-TJA-250. Oyo Yakuri. 1995 ; 49: 163-171.
24. Lu J., Chan Y. -K, Gamble GD, Poppitt SD, Cooper GJS. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type-2 diabetic patients. Drug Metab Dispos. 2007 ; 35: 221-227.
25. Grant DM, Morike K., Eichelbaum M., Meyer UA Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Investig. 1990 ; 85: 968-972.
26. Othman A., Lu J., Sunderland T., Cooper GJS. Development and validation of a rapid HPLC method for the simultaneous determination of triethylenetetramine and its two main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 860: 42-48.
27. Wichmann KA, Boyd PDW, S¶hnel T., Allen GR, Phillips ARJ, Cooper GJS. Characterization of dicarboxylic salts of protonated triethylenetetramine useful for the treatment of copper-related pathologies. Crystal Growth Design. 2007 ; 7: 1844-1850.
28. Notarianni LJ, Dobrocky P., Godlewski G., Jones RW, Bennett PN Caffeine as a metabolic probe: NAT2 phenotyping. Br J Clin Pharmacol. 1996 ; 41: 169-173.
29. Tang BK, Kadar D., Qian L., Iriah J., Yip J., Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther. 1991 ; 49: 648-657.
30. Fink K., Adams WS, Pfleiderer W. A new urinary pyrimidine, 5-acetylamino-6-amino-3-methyluracil. J Biol Chem. 1964 ; 239: 4250-4256.
31. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res. 1997 ; 35: 2-3.
32. Lu J., Chan Y. -K, Poppitt SD, Cooper GJS. Determination of triethylenetetramine (TETA) and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry (LC-MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 859: 62-68.
33. Cho H. -Y, Blum RA, Sunderland T., Cooper GJS, Jusko WJ Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. J Clin Pharmacol. 2009 ; 49: 916-928.
34. Hayashi H, Suzuki R, Wakusawa S. Wilsonĝ€™s disease and its pharmacological treatment. Yakugaku Zasshi. 2004;124:711-724. 35. Shimizu N, Yamaguchi Y, Aoki T. Treatment and management of Wilsonĝ€™s disease. Pediatr Int. 1999;41:419-422.
35. Shimizu N, Yamaguchi Y, Aoki T. Treatment and management of Wilsonĝ€™s disease. Pediatr Int. 1999;41:419-422.
36. Condamine L., Hermine O., Alvin P., Levine M., Rey C., Courtecuisse V. Acquired sideroblastic anaemia during treatment of Wilsonĝ€™s disease with triethylene tetramine dihydrochloride. Br J Haematol. 1993 ; 83: 166-168.
37. Perry AR, Pagliuca A., Fitzsimons EJ, Mufti GJ, Williams R. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol. 1996 ; 64: 69-72.
38. American Red Cross Blood Services. Red Cell Transfusion Guidelines. http://www.newenglandblood.org/professional/redcellguide.htm. Accessed July 23, 2007.
39. Wormhoudt LW, Commandeur JN, Vermeulen NP Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999 ; 29: 59-124.
40. Casero RA Jr, Pegg AE Spermidine/spermine N1acetyltransferase: the turning point in polyamine metabolism. FASEB J. 1993 ; 7: 653-661.
41. Seiler N. Catabolism of polyamines. Amino Acids. 2004 ; 26: 217-233.